Answers are grounded in this paper and cite their sources.
This article provides an overview of drugs for metastatic colorectal cancer that are currently being evaluated in clinical trials. We discuss possible drug combinations and outlooks of their use in different lines of therapy. In addition to VEGF and EGFR inhibitors, we describe the molecules with fundamentally new mechanisms of action that can significantly expand the list of anticancer agents and increase the number of possible lines of therapy.
No takes yet. Share an insight, caveat, or question.
Забелин et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: